Surging Oil Prices Trigger Market Jitters
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 26 2026
0mins
Should l Buy HIMS?
Source: Fool
- Surging Oil Prices: Oil prices have surged past $100 per barrel for the first time in 2026, marking a significant increase from below $60 at the start of the year, which has raised investor concerns about potential impacts on economic growth and profitability across various sectors.
- Supply Disruption Impact: Approximately 20% of oil supply has been disrupted for about nine days due to the largest supply disruption in history, with no spare capacity available to alleviate the situation, intensifying fears of sustained high oil prices.
- S&P 500 Changes: The S&P 500 index has undergone changes, removing four companies including Match Group, while adding four others like Vertiv, reflecting strong demand for AI and connectivity infrastructure and indicating a shift in industry trends.
- Hims & Hers Stock Surge: Hims & Hers stock jumped significantly following an unexpected partnership with Novo Nordisk, resolving a legal dispute and allowing the sale of FDA-approved weight loss drugs, which is expected to boost revenue and improve market sentiment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 24.240
Low
16.50
Averages
32.95
High
60.00
Current: 24.240
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Reports Revenue Growth Amid Shrinking Margins
- Revenue Growth: Hims & Hers reported first-quarter 2026 revenue of $608.1 million, a 4% year-over-year increase, indicating continued subscriber growth across its weight-loss, sexual health, dermatology, and primary care sectors, despite profitability challenges.
- Profit Decline: The company posted a net loss of $92.1 million compared to a net income of $49.5 million a year earlier, with adjusted EBITDA falling from $91.1 million to $44.3 million and gross margin shrinking from 73% to 65%, highlighting the economic pressures from its strategic shift.
- Strategic Shift: Hims transitioned from high-margin compounded GLP-1 weight-loss drugs to branded products like Novo Nordisk's, which reduced regulatory risks but compressed margins and increased operating costs, resulting in a more than 12% drop in stock price following the earnings release.
- International Expansion: The acquisition of ZAVA allows Hims to tap into the European market with approximately $100 million in annual revenue and an established telemedicine infrastructure, while the company plans to expand into hormone optimization and preventative diagnostics, despite facing high valuation and execution risks.
See More
Hims & Hers Health Earnings Analysis and Future Prospects
- Revenue Outlook Adjustment: Hims & Hers raises its 2023 revenue forecast to between $2.8 billion and $3 billion, yet significantly lowers adjusted EBITDA guidance to between $275 million and $350 million, indicating risks of margin compression as the company pivots to branded weight-loss drugs.
- Quarterly Performance Review: Q1 sales increased 4% year-over-year to $608.1 million, falling short of the $600 million to $625 million guidance, with U.S. revenue down 8% to $529.9 million, while international revenue surged from $7.3 million last year to $78.2 million, highlighting market disparities.
- User Growth vs. Revenue Decline: Monthly revenue per subscriber dropped 6% year-over-year to $80, even as subscriber numbers grew 9% to over 2.58 million, indicating challenges in revenue quality despite expanding the user base.
- Future Outlook and Risks: Hims expects Q2 revenue between $680 million and $700 million, with adjusted EBITDA between $35 million and $55 million; while growth potential exists, concerns over margin compression may impact investor confidence.
See More
Hims & Hers Health Stock Faces Continued Decline Amid Earnings Miss
- Stock Decline Trend: Hims & Hers Health's stock closed near $25 on Tuesday, falling below the 61.8% Fibonacci retracement level of its 2022-2025 rally, indicating a weakening technical setup that may signal a broader trend reversal.
- Earnings Miss: The company missed Street forecasts in its Q1 2026 financials, leading to further declines in stock price, reflecting market concerns about future growth, especially after a dramatic rise from below $5 in 2022 to over $70 last year.
- Technical Support Analysis: HIMS has lost the 23.6%, 38.2%, and 50% retracement levels, with the next major support zone near the 78.6% retracement area in the low $20 range; a breach of this level could exacerbate market panic.
- Future Outlook: Despite challenges, Hims & Hers forecasts 2026 revenue between $2.8 billion and $3.0 billion, targeting over 100,000 monthly weight loss subscriber additions, demonstrating the company's confidence in long-term growth.
See More
Hims & Hers Health Misses Q1 Forecasts Amid Strategic Shift
- Disappointing Earnings: Hims & Hers Health (HIMS) missed Q1 2026 financial forecasts, leading to a ~15% stock drop, despite raising its full-year revenue outlook to $2.8B-$3.0B, indicating a positive long-term perspective.
- Profitability Pressure: While HIMS's revenue outlook is optimistic, its adjusted EBITDA forecast fell short of analyst expectations, highlighting potential short-term profitability challenges as the company pivots towards branded drugs.
- Divergent Analyst Views: Citi analyst maintains a Neutral rating, suggesting that the ongoing transformation may hurt short-term profitability, whereas Needham analyst raised the price target from $30 to $35, arguing that long-term gains could offset near-term margin pressures.
- Strategic Partnership Impact: The collaboration with Novo Nordisk (NVO) is seen as crucial for attracting new subscribers, with analysts noting that this partnership will help HIMS build durable customer relationships and cross-sell across multiple care categories, despite potential short-term margin impacts.
See More
Hims & Hers Reports Q1 Revenue Miss and Loss Amid Strategic Shift
- Performance Decline: Hims & Hers shares fell approximately 12% in after-hours trading due to missing Q1 revenue estimates and posting an unexpected loss, indicating pressure on margins from the shift towards branded GLP-1 weight-loss drugs.
- Revenue Outlook Raised: Despite challenges, the company raised its full-year revenue outlook, suggesting that partnerships with Novo Nordisk and international expansion could support future sales, reflecting confidence in market potential.
- Increased Restructuring Costs: Hims & Hers noted that transitioning away from compounded versions of GLP-1 drugs will incur restructuring costs, which may impact financial performance in the short term but is expected to optimize the product line in the long run.
- Profitability Expectations: CFO Yemi Okupe stated that the company expects to return to profitability by 2027 while focusing on positive operating cash flow, indicating a commitment to future financial health.
See More
Significant Stock Movements for Vestis and Others
- Vestis Earnings Beat: Vestis surged over 30% after reporting fiscal Q2 results that exceeded expectations, along with an upward revision of its fiscal 2026 EBITDA outlook, indicating strong growth potential in the apparel sector.
- Zebra's Strong Performance: Zebra Technologies reported Q1 earnings of $4.75 per share, surpassing the $4.25 expected by analysts, with revenues of $1.5 billion, and Q2 guidance also exceeded estimates, highlighting ongoing growth in the automation sector.
- Ralliant's Earnings Surprise: Ralliant's adjusted Q1 earnings of 57 cents per share exceeded both company guidance and FactSet consensus of 49 cents, leading to a 14% stock increase, reflecting robust demand in the high-precision instruments market.
- Hub Group Financial Restatement: Hub Group's shares fell over 10% after announcing a restatement of its year-end 2023 and 2024 results, which may negatively impact investor confidence.
See More
Hims & Hers Reports Revenue Growth Amid Shrinking Margins
- Revenue Growth: Hims & Hers reported first-quarter 2026 revenue of $608.1 million, a 4% year-over-year increase, indicating continued subscriber growth across its weight-loss, sexual health, dermatology, and primary care sectors, despite profitability challenges.
- Profit Decline: The company posted a net loss of $92.1 million compared to a net income of $49.5 million a year earlier, with adjusted EBITDA falling from $91.1 million to $44.3 million and gross margin shrinking from 73% to 65%, highlighting the economic pressures from its strategic shift.
- Strategic Shift: Hims transitioned from high-margin compounded GLP-1 weight-loss drugs to branded products like Novo Nordisk's, which reduced regulatory risks but compressed margins and increased operating costs, resulting in a more than 12% drop in stock price following the earnings release.
- International Expansion: The acquisition of ZAVA allows Hims to tap into the European market with approximately $100 million in annual revenue and an established telemedicine infrastructure, while the company plans to expand into hormone optimization and preventative diagnostics, despite facing high valuation and execution risks.
See More
Hims & Hers Health Earnings Analysis and Future Prospects
- Revenue Outlook Adjustment: Hims & Hers raises its 2023 revenue forecast to between $2.8 billion and $3 billion, yet significantly lowers adjusted EBITDA guidance to between $275 million and $350 million, indicating risks of margin compression as the company pivots to branded weight-loss drugs.
- Quarterly Performance Review: Q1 sales increased 4% year-over-year to $608.1 million, falling short of the $600 million to $625 million guidance, with U.S. revenue down 8% to $529.9 million, while international revenue surged from $7.3 million last year to $78.2 million, highlighting market disparities.
- User Growth vs. Revenue Decline: Monthly revenue per subscriber dropped 6% year-over-year to $80, even as subscriber numbers grew 9% to over 2.58 million, indicating challenges in revenue quality despite expanding the user base.
- Future Outlook and Risks: Hims expects Q2 revenue between $680 million and $700 million, with adjusted EBITDA between $35 million and $55 million; while growth potential exists, concerns over margin compression may impact investor confidence.
See More
Hims & Hers Health Stock Faces Continued Decline Amid Earnings Miss
- Stock Decline Trend: Hims & Hers Health's stock closed near $25 on Tuesday, falling below the 61.8% Fibonacci retracement level of its 2022-2025 rally, indicating a weakening technical setup that may signal a broader trend reversal.
- Earnings Miss: The company missed Street forecasts in its Q1 2026 financials, leading to further declines in stock price, reflecting market concerns about future growth, especially after a dramatic rise from below $5 in 2022 to over $70 last year.
- Technical Support Analysis: HIMS has lost the 23.6%, 38.2%, and 50% retracement levels, with the next major support zone near the 78.6% retracement area in the low $20 range; a breach of this level could exacerbate market panic.
- Future Outlook: Despite challenges, Hims & Hers forecasts 2026 revenue between $2.8 billion and $3.0 billion, targeting over 100,000 monthly weight loss subscriber additions, demonstrating the company's confidence in long-term growth.
See More
Hims & Hers Health Misses Q1 Forecasts Amid Strategic Shift
- Disappointing Earnings: Hims & Hers Health (HIMS) missed Q1 2026 financial forecasts, leading to a ~15% stock drop, despite raising its full-year revenue outlook to $2.8B-$3.0B, indicating a positive long-term perspective.
- Profitability Pressure: While HIMS's revenue outlook is optimistic, its adjusted EBITDA forecast fell short of analyst expectations, highlighting potential short-term profitability challenges as the company pivots towards branded drugs.
- Divergent Analyst Views: Citi analyst maintains a Neutral rating, suggesting that the ongoing transformation may hurt short-term profitability, whereas Needham analyst raised the price target from $30 to $35, arguing that long-term gains could offset near-term margin pressures.
- Strategic Partnership Impact: The collaboration with Novo Nordisk (NVO) is seen as crucial for attracting new subscribers, with analysts noting that this partnership will help HIMS build durable customer relationships and cross-sell across multiple care categories, despite potential short-term margin impacts.
See More
Hims & Hers Reports Q1 Revenue Miss and Loss Amid Strategic Shift
- Performance Decline: Hims & Hers shares fell approximately 12% in after-hours trading due to missing Q1 revenue estimates and posting an unexpected loss, indicating pressure on margins from the shift towards branded GLP-1 weight-loss drugs.
- Revenue Outlook Raised: Despite challenges, the company raised its full-year revenue outlook, suggesting that partnerships with Novo Nordisk and international expansion could support future sales, reflecting confidence in market potential.
- Increased Restructuring Costs: Hims & Hers noted that transitioning away from compounded versions of GLP-1 drugs will incur restructuring costs, which may impact financial performance in the short term but is expected to optimize the product line in the long run.
- Profitability Expectations: CFO Yemi Okupe stated that the company expects to return to profitability by 2027 while focusing on positive operating cash flow, indicating a commitment to future financial health.
See More
Significant Stock Movements for Vestis and Others
- Vestis Earnings Beat: Vestis surged over 30% after reporting fiscal Q2 results that exceeded expectations, along with an upward revision of its fiscal 2026 EBITDA outlook, indicating strong growth potential in the apparel sector.
- Zebra's Strong Performance: Zebra Technologies reported Q1 earnings of $4.75 per share, surpassing the $4.25 expected by analysts, with revenues of $1.5 billion, and Q2 guidance also exceeded estimates, highlighting ongoing growth in the automation sector.
- Ralliant's Earnings Surprise: Ralliant's adjusted Q1 earnings of 57 cents per share exceeded both company guidance and FactSet consensus of 49 cents, leading to a 14% stock increase, reflecting robust demand in the high-precision instruments market.
- Hub Group Financial Restatement: Hub Group's shares fell over 10% after announcing a restatement of its year-end 2023 and 2024 results, which may negatively impact investor confidence.
See More
